The power of immunotherapy plus platinum-based chemotherapy for locally advanced or early stage non-small cell lung cancer.
作者信息
Hofman Paul
机构信息
Université Côte d'Azur, CHU Nice, FHU OncoAge, Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, Franc.
Université Côte d'Azur, CNRS, INSERM, IRCAN, FHU OncoAge, Team 4, Nice, France.
出版信息
Ann Transl Med. 2020 Mar;8(5):151. doi: 10.21037/atm.2020.01.91.
Abstract
摘要
相似文献
1
The power of immunotherapy plus platinum-based chemotherapy for locally advanced or early stage non-small cell lung cancer.免疫疗法联合铂类化疗用于局部晚期或早期非小细胞肺癌的疗效
Ann Transl Med. 2020 Mar;8(5):151. doi: 10.21037/atm.2020.01.91.
2
Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.基于生物标志物检测的定制辅助化疗可能改善非小细胞肺癌完全切除患者的生存率。
Anticancer Res. 2017 May;37(5):2501-2507. doi: 10.21873/anticanres.11591.
3
Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines.艾迪注射液联合铂类化疗方案治疗ⅢB/Ⅳ期非小细胞肺癌的 Meta 分析：遵循 PRISMA 指南的 42 项 RCT 研究的汇总分析。
J Ethnopharmacol. 2018 Jul 15;221:137-150. doi: 10.1016/j.jep.2018.04.013. Epub 2018 Apr 12.
4
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.一项关于一线化疗治疗局部晚期或转移性非小细胞肺癌成人患者的临床疗效的系统评价。
Thorax. 2015 Apr;70(4):359-67. doi: 10.1136/thoraxjnl-2014-205914. Epub 2015 Feb 6.
5
Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy.接受铂类诱导化疗的局部晚期非小细胞肺癌（LA-NSCLC）患者中，肿大纵隔淋巴结（N2>2.5 cm）的预后影响。
Lung Cancer. 2000 Nov;30(2):107-16. doi: 10.1016/s0169-5002(00)00128-8.
6
Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.晚期肺癌的联合化疗和程序性死亡受体 1/程序性死亡配体 1 抑制剂治疗的毒性管理。
Cancer Treat Rev. 2020 Apr;85:101979. doi: 10.1016/j.ctrv.2020.101979. Epub 2020 Feb 4.
7
Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis.培美曲塞联合铂类双药化疗作为晚期非鳞状非小细胞肺癌一线治疗的疗效：一项系统评价和荟萃分析。
Onco Targets Ther. 2016 Mar 14;9:1471-6. doi: 10.2147/OTT.S96160. eCollection 2016.
8
The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience.不断演变的局部晚期非小细胞肺癌格局：基于既往证据与经验
Crit Rev Oncol Hematol. 2015 Nov;96(2):319-27. doi: 10.1016/j.critrevonc.2015.05.020. Epub 2015 Jun 7.
9
Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).在一线使用非铂类方案预处理的非小细胞肺癌患者中，伊立替康/顺铂与培美曲塞/顺铂挽救治疗的比较：希腊肿瘤学研究组（HORG）的一项随机II期研究
Clin Transl Oncol. 2017 Mar;19(3):317-325. doi: 10.1007/s12094-016-1532-y. Epub 2016 Aug 4.
10
Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.晚期非小细胞肺癌患者铂类化疗的基因组分析确定了SMYD2中具有预后价值的种系变异。
Cancer Treat Res Commun. 2018;15:21-31. doi: 10.1016/j.ctarc.2018.02.003. Epub 2018 Mar 1.
引用本文的文献
1
Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study.使用免疫疗法的非小细胞肺癌患者生存的种族差异调查：一项德克萨斯州的研究。
Front Oncol. 2023 Jan 9;12:1092355. doi: 10.3389/fonc.2022.1092355. eCollection 2022.
本文引用的文献
1
Conversion therapy from N3 unresectable lung adenocarcinoma to radical surgery: a case report.从不可切除的N3期肺腺癌转化为根治性手术：一例病例报告
Ann Transl Med. 2019 Oct;7(20):590. doi: 10.21037/atm.2019.09.113.
2
Optimal Surgical Timing After Neoadjuvant Therapy for Stage IIIa Non-Small Cell Lung Cancer.新辅助治疗后 IIIa 期非小细胞肺癌的最佳手术时机。
Ann Thorac Surg. 2020 Mar;109(3):842-847. doi: 10.1016/j.athoracsur.2019.09.076. Epub 2019 Nov 19.
3
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.可切除非小细胞肺癌新辅助 PD-1 阻断治疗病理反应的 T 细胞克隆动力学的房室分析。
Clin Cancer Res. 2020 Mar 15;26(6):1327-1337. doi: 10.1158/1078-0432.CCR-19-2931. Epub 2019 Nov 21.
4
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort.程序性死亡配体1的表达受组织样本大小影响。在欧洲胸部肿瘤学平台Lungscape队列的I-III期非小细胞肺癌患者中，基于组织微阵列进行评分并与切除术进行交叉验证。
Mod Pathol. 2020 May;33(5):792-801. doi: 10.1038/s41379-019-0383-9. Epub 2019 Nov 18.
5
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.基于面板的肺腺癌肿瘤突变负荷的时空异质性：从技术伪影中分离生物学。
J Thorac Oncol. 2019 Nov;14(11):1935-1947. doi: 10.1016/j.jtho.2019.07.006. Epub 2019 Jul 23.
6
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.免疫检查点抑制剂作为一线治疗方案，单独或联合化疗用于晚期非小细胞肺癌：一项系统评价和网络荟萃分析。
Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30.
7
Changes in store for early-stage non-small cell lung cancer.早期非小细胞肺癌即将发生的变化。
J Thorac Dis. 2019 May;11(5):2117-2125. doi: 10.21037/jtd.2019.05.34.
8
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?免疫肿瘤时代的液体活检：它是否已经准备好供癌症患者常规使用？
Ann Oncol. 2019 Sep 1;30(9):1448-1459. doi: 10.1093/annonc/mdz196.
9
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer.如何将免疫治疗作为晚期/转移性非小细胞肺癌的一线治疗进行优化。
Ann Oncol. 2019 Jun 1;30(6):884-896. doi: 10.1093/annonc/mdz109.
10
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).国际肺癌专家小组对人用药品委员会（CHMP）批准度伐利尤单抗用于III期非小细胞肺癌（NSCLC）的决定的立场。
Ann Oncol. 2019 Feb 1;30(2):161-165. doi: 10.1093/annonc/mdy553.
Zotero 插件